Multivariate logistic regression analyses revealed that the decision to prescribe PEGV?+?SSA vs. PEGV was significantly correlated with the presence of detectable tumor at baseline (p?=?0.002) and with the IGF-I response to previous therapy reflected in the ∆ IGF-I (p?=?0.001) (Table 2). Here, IGF1 is linked to neoplasm.